(Q50862543)

English

Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.

scientific article published on 13 March 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289852%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289852%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

corrigendum / erratum

Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.

0 references

Federico Piacentini

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289852%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289852%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Maria Vittoria Dieci

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289852%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289852%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Pierfranco Conte

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289852%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Valentina Guarneri

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289852%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

author name string

A Frassoldati

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289852%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

D Generali

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289852%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

G Bisagni

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289852%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

L Cavanna

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289852%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

K Cagossi

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289852%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

A Michelotti

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289852%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

R Berardi

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289852%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

G Banna

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289852%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

A Goubar

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289852%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

G Ficarra

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289852%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

language of work or name

0 references

publication date

13 March 2017

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289852%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289852%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

163

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289852%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289852%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

295-302

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289852%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

https://scigraph.springernature.com/pub.10.1007/s10549-017-4191-y

0 references

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4191-Y

21 January 2018

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4191-Y

21 January 2018

A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4191-Y

21 January 2018

Ki67 measured after neoadjuvant chemotherapy for primary breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4191-Y

21 January 2018

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4191-Y

21 January 2018

Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4191-Y

21 January 2018

Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4191-Y

21 January 2018

The immune system and hormone-receptor positive breast cancer: Is it really a dead end?

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4191-Y

21 January 2018

Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4191-Y

21 January 2018

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4191-Y

21 January 2018

Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4191-Y

21 January 2018

Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4191-Y

21 January 2018

Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4191-Y

21 January 2018

Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4191-Y

21 January 2018

Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4191-Y

21 January 2018

Identifiers

10.1007/S10549-017-4191-Y

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289852%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289852%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50862543&oldid=1165378015"